Sutro Biopharma (STRO) Competitors

ORIC Pharmaceuticals (NASDAQ:ORIC) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

Does the media refer more to ORIC or STRO?

In the previous week, ORIC Pharmaceuticals had 13 more articles in the media than Sutro Biopharma. MarketBeat recorded 14 mentions for ORIC Pharmaceuticals and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.32 beat ORIC Pharmaceuticals' score of 0.35 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ORIC Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of ORIC or STRO?

95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 5.9% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts rate ORIC or STRO?

ORIC Pharmaceuticals currently has a consensus price target of $18.71, indicating a potential upside of 143.68%. Sutro Biopharma has a consensus price target of $11.13, indicating a potential upside of 528.53%. Given Sutro Biopharma's higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than ORIC Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ORIC Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sutro Biopharma	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Is ORIC or STRO more profitable?

ORIC Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -77.01%. ORIC Pharmaceuticals' return on equity of -44.54% beat Sutro Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ORIC Pharmaceuticals	N/A	-44.54%	-40.72%
Sutro Biopharma	-77.01%	-101.89%	-28.69%

Which has more volatility & risk, ORIC or STRO?

ORIC Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.

Which has better valuation and earnings, ORIC or STRO?

ORIC Pharmaceuticals has higher earnings, but lower revenue than Sutro Biopharma. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ORIC Pharmaceuticals	N/A	N/A	-$100.70M	-$1.82	-4.22
Sutro Biopharma	$153.73M	0.95	-$106.79M	-$1.61	-1.10

Does the MarketBeat Community prefer ORIC or STRO?

Sutro Biopharma received 63 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 74.19% of users gave ORIC Pharmaceuticals an outperform vote while only 66.00% of users gave Sutro Biopharma an outperform vote.

Company	Underperform	Outperform
ORIC Pharmaceuticals	Outperform Votes 69 74.19%	Underperform Votes 24 25.81%
Sutro Biopharma	Outperform Votes 132 66.00%	Underperform Votes 68 34.00%

Summary

Sutro Biopharma beats ORIC Pharmaceuticals on 9 of the 17 factors compared between the two stocks.